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Abstract  40 
Background  41 
The cytosolic 5’-nucleotidase II gene (NT5C2, cN-II) is associated with disorders 42 
characterised by psychiatric and psychomotor disturbances. Common psychiatric risk 43 
alleles at the NT5C2 locus reduce expression of this gene in the foetal and adult brain, but 44 
downstream biological risk mechanisms remain elusive.   45 
Methods 46 
Distribution of the NT5C2 protein in the human DLPFC and cortical human neural progenitor 47 
cells (hNPCs) was determined using immunostaining, publicly available expression data, 48 
and reverse transcription quantitative PCR (RT-qPCR). Phosphorylation quantification of 49 
AMPK-alpha (Thr172) and ribosomal protein S6 (RPS6) (Ser235/Ser236) were performed 50 
using western blotting, to infer the degree of activation of AMPK signalling and the rate of 51 
protein translation. Knockdowns were induced in hNPCs and Drosophila melanogaster 52 
using RNA interference (RNAi). Transcriptomic profiling of hNPCs was performed using 53 
microarrays, and motility behaviour was assessed in flies using the climbing assay. 54 
Results 55 
Expression of NT5C2 was higher during neurodevelopment, and was neuronally enriched 56 
in the adult human cortex. Knockdown in hNPCs affected AMPK signalling, a major nutrient 57 
sensing mechanism involved in energy homeostasis, and protein translation. Transcriptional 58 
changes implicated in protein translation were observed in knockdown hNPCs, and 59 
expression changes to genes related to AMPK signalling and protein translation were 60 
confirmed using RT-qPCR. The knockdown in Drosophila was associated with drastic 61 
climbing impairment.  62 
Conclusions 63 
We provide an extensive neurobiological characterisation of the psychiatric risk gene 64 
NT5C2, describing its previously unknown role on the regulation of AMPK signalling and 65 
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protein translation in neural stem cells, and its association with Drosophila melanogaster 66 
motility behaviour. 67 
 68 
  69 
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Introduction  70 
The cytosolic 5’-nucleotidase II gene (NT5C2, cN-II) encodes a phosphatase associated 71 
with disorders characterised by psychiatric and psychomotor disturbances, including major 72 
psychiatric conditions (1-4), Parkinson’s disease (5), and spastic paraplegia (6). The NT5C2 73 
enzyme cleaves purinergic monophosphate nucleotides, with particularly high affinity for 74 
adenosine monophosphate (AMP) (7). These energetic molecules are required for the 75 
extensive transcriptional reprogramming governing cell maintenance, proliferation, 76 
migration, and differentiation during neurodevelopment (8-11), and are implicated in adult 77 
brain function and psychiatric and psychomotor disturbances (12-14).  78 
 79 
We previously showed that common psychiatric risk variants at the NT5C2 locus are 80 
associated with reduced neurological expression of this gene in population controls and in 81 
the foetus (3). As a key regulator of intracellular AMP, we hypothesise that NT5C2 82 
modulates the AMP-activated protein kinase (AMPK), a major energy homeostasis regulator 83 
(15, 16). AMPK signalling has been previously associated with psychiatric disorders (17-84 
20), NT5C2 function in muscle fibres (21), and also with protein translation (22-27) and 85 
motility behaviour (17, 28, 29), which are highly energy consuming processes. However, the 86 
underlying gene regulatory networks that mediate the effect of NT5C2 on AMPK signalling 87 
in the context of psychiatric disorders, cell types or developmental time point remains 88 
unclear. 89 
 90 
Here, we have investigated NT5C2 expression, function and protein distribution in the 91 
human brain and neural progenitor cells (hNPCs); its role on the regulation of AMPK 92 
signalling and protein translation, and association with climbing behaviour in Drosophilla 93 
melanogaster. First, to extend our previous work, we identified the major cell types 94 
expressing NT5C2 in the adult brain, which showed that NT5C2 protein is more expressed 95 
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in neurons relative to glial cells. Second, we provide complementary evidence that this gene 96 
is more expressed during neurodevelopment, suggesting an important role at this 97 
developmental stage. Third, we investigate the effects of NT5C2 loss-of-function on the 98 
phosphorylation of AMPK-alpha (Thr172) and ribosomal protein S6 (Ser235/Ser236) in 99 
hNPCs, suggesting a regulatory role on AMPK signalling and protein translation. Finally, 100 
based on evidence from genetic studies implicating NT5C2 in psychomotor disturbances, 101 
we tested the effect of a loss-of-function on climbing behaviour using Drosophila 102 
melanogaster (D. melanogaster) as model organism, confirming a role in motility behaviour. 103 
The present study provides an extensive neurobiological characterisation of NT5C2, 104 
describing its hitherto unknown relationship with AMPK signalling and protein translation in 105 
neural stem cells, and a role for motility behaviour in fly. Ultimately, these data demonstrate 106 
biological mechanisms associated with NT5C2 that may explain its association with 107 
psychiatric disorders. 108 
 109 
  110 
Methods and Materials 111 
See Supplemental Information for further details on Methods and Materials. 112 
 113 
Brain samples 114 
To identify cell-type specific expression of NT5C2 in the adult cortex, we obtained samples 115 
from unaffected controls from the Medical Research Council London Neurodegenerative 116 
Disease Brain Bank, at the Institute of Psychiatry, Psychology & Neuroscience, King’s 117 
College London (UK Human Tissue Authority licence #12293).  118 
 119 
Immunohisto- and cytochemistry 120 
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Brain sections were deparaffinised and submitted to antigen retrieval and autofluorescence 121 
removal protocols (Supplemental Information). hNPCs were fixed and processed as 122 
previously described (30). The following primary antibodies were used: NT5C2 (M02-3C1) 123 
(Abnova, Taipei, Taiwan), IBA1 (Menarini Diagnostics, Winnersh, United Kingdom), GFAP 124 
(Dako Agilent, Santa Clara, United States), MAP2, Parvalbumin and Beta-III-Tubulin 125 
(Abcam, Cambridge, United Kingdom). Fluorescently labelled secondary antibodies 126 
included Goat or Rabbit Alexa 488, 568 and 633 antibodies (Thermo Fisher Scientific, 127 
Waltham, Massachusetts, United States).  128 
 129 
Cell lines 130 
We used hNPCs from the CTX0E16 neural stem cell line (31) or from human induced 131 
pluripotent stem cells (hiPSCs) from an unaffected control (30), as well as human embryonic 132 
kidney cells 293T (HEK293T) to identify the subcellular distribution and function of NT5C2. 133 
The CTX0E16 neural cell line (31) was obtained from ReNeuron Ltd. under a Material 134 
Transfer Agreement. All lines were derived and maintained as described in the 135 
Supplemental Information and elsewhere (30, 31). 136 
 137 
RNA and protein isolation and quantification 138 
To identify gene and protein expression and phosphorylation differences in knockdown or 139 
overexpression cultures, we isolated total RNA or protein using TRI Reagent or RIPA Buffer 140 
supplemented with Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher 141 
Scientific), respectively. Reverse transcriptase quantitative polymerase chain reaction (RT-142 
qPCR), RNA quality control and western blotting details are available in the Supplemental 143 
Information. Primary antibodies for western blotting included: AMPK-alpha (D6) and 144 
phospho-AMPK-alpha (Thr172) (Santa Cruz Biotechnology, Dallas, Texas, United States), 145 
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total RPS6 (54d2) and phospho-RPS6 (Ser235/Ser236) (Cell Signalling, Danvers, 146 
Massachusetts, United States).  147 
 148 
Fly stocks and climbing assay 149 
We used Gal4-upstream activated sequences (UAS) (32) to knockdown CG32549 in specific 150 
tissues, by crossing a CG32549-RNAi line (KD: v30079) with UAS lines where Gal4 151 
expression (and thus knockdown) is driven throughout the body (ACT5C: BL4414), in 152 
neurons and neural progenitor cells (ELAV: BL8765), or in gut (GUT: DGRC113094). 153 
Crosses were submitted to the negative geotaxis assay (33), a cost-effective test that has 154 
been previously used to investigate the association between genes and motility (34-36). 155 
Climbing success was calculated as % flies per tube which climbed over an arbitrary mark, 156 
and survival was determined as % flies alive 17-20 days post emergence, out of starting 157 
flasks containing 20 flies (n = 4+ flasks per condition).  158 
 159 
Statistical analysis 160 
To infer statistical differences between more than two independent groups, we used one-161 
way ANOVAs followed by Tukey post hoc tests (for normally distributed values), or Kruskal-162 
Wallis tests followed by Dunn’s tests (for non-normally distributed values). To infer 163 
differences between two groups, we performed two-way independent parametric t-tests. 164 
Multiple testing correction was applied as described in Results. Microarray expression data 165 
were analysed using linear regressions (see Supplemental Methods). Gene overlap 166 
significance was calculated in R (package ‘GeneOverlap’) using the Fisher’s exact test. 167 
Statistical analyses were performed in R and SPSS. 168 
 169 
 170 
Results  171 
9 
 
Expression of NT5C2 is enriched in neurons in the adult brain  172 
To extend our previous work and investigate the relationship between NT5C2 expression 173 
and psychiatric disorders, we investigated which cell types express this gene in the adult 174 
brain. We examined single-cell RNA-sequencing data from the mouse cortex (37), which 175 
revealed cell-type specific profiles of NT5C2 expression (Kruskal-Wallis test, H(4) = 52.44, 176 
P < 0.001). Post hoc analyses confirmed that NT5C2 was more frequently observed in 177 
pyramidal neurons (95% percentile = 3 (counts)) than astrocytes (95% percentile = 1, Dunn’s 178 
post hoc test, corrected P < 0.001), and in interneurons (95% percentile = 3) rather than 179 
microglia (95% percentile = 2.05, corrected P < 0.01) or astrocytes (95% percentile = 1, 180 
corrected P < 0.001; Supplemental Figure 1). 181 
  182 
To investigate correlates with the human cortex, we performed a series of 183 
immunocolocalisation experiments using post-mortem brains. Initially, we investigated the 184 
specificity of an antibody for NT5C2 by probing HEK293T cells and CTX0E16 hNPCs 185 
overexpressing myc-NT5C2 (Supplemental Figures 2 and 4), and a loss-of-function in 186 
hNPCs (Figure 3C). While immunolabelling of endogenous expression and heterologous 187 
systems may produce different results due to existence of tissue-specific isoforms, these 188 
findings corroborate the suitability of this antibody for our aims. This antibody was used to 189 
investigate the distribution of NT5C2 in the prefrontal cortex using standard 190 
immunoperoxidase staining with DAB as chromogen (Supplemental Figure 3). A qualitative 191 
analysis of NT5C2-positive immunostaining with Nissl counter-stain to reveal cell 192 
morphology suggested that NT5C2 was present in neurons, glia and the surrounding 193 
neuropil. However, we noted that not all putative glial cells expressed NT5C2 (red arrows; 194 
Supplemental Figure 3), corroborating a previous observation by the Human Protein Atlas 195 
that expression is lower in these cells (38). To confirm this, we quantified the cell type-196 
10 
 
specific expression profile of NT5C2 in the cortex by quantifying immuno-co-localisation of 197 
this protein with markers of mature neurons (microtubule-associated protein 2, MAP2), a 198 
sub-class of gamma-amino butyric acid (GABA) interneurons (parvalbumin, PARVALB), 199 
astrocytes (glial fibrillary acidic protein, GFAP), and microglia (ionized calcium-binding 200 
adapter molecule 1, IBA1) (Figures 1A-E). These cells were selected based on the wealth 201 
of evidence implicating them in the pathophysiology of psychiatric disorders (39-42). Co-202 
localisation quantification was performed using a semi-automated ImageJ macro (43, 44) 203 
(details in Supplemental Methods), which revealed cell type specific profiles of NT5C2 204 
expression, based on the co-localisation with these markers (One-way ANOVA, F (3,44) = 205 
39.12, P < 0.001, n = 4 unaffected controls, 4 technical replicates each, 20 fields of view per 206 
technical replicate). Co-localisation occurred more frequently with neuron and interneuron 207 
than non-neuronal markers (Tukey post hoc tests: MAP2 (7.5% (cluster colocalization 208 
relative to all clusters in image) ± 2.0 (standard deviation)), PARVALB (6.9% ± 2.1), GFAP 209 
(3.13% ± 1.1), IBA1 (1.4% ± 0.93); P < 0.001 for all comparisons, except MAP2 vs. 210 
PARVALB, and GFAP vs. IBA1 (P > 0.05); Figure 1E). NT5C2 expression at the transcript 211 
and protein levels appear to be highly-expressed in neurons within the adult brain, consistent 212 
with recent observations that risk variants implicated in schizophrenia are enriched for 213 
neuronal genes (40). 214 
 215 
NT5C2 is highly expressed and ubiquitously distributed in hNPCs  216 
The role of NT5C2 in psychiatric disorders has been previously hypothesised to commence 217 
during neurodevelopment, a period underscored by complex processes implicated in major 218 
psychiatric disorders (45), with this risk mechanism persisting in the adult brain (3). The 219 
contribution of NT5C2 to neurobiology, however, should be greater at the developmental 220 
stage when this gene is more expressed. Thus, we investigated NT5C2 expression in the 221 
Human Brain Transcriptome atlas (46), which revealed that expression peaks during 222 
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neurodevelopment (Figure 2A). Considering that established cell lines are cost-effective 223 
and easy-to-use tools to study neurodevelopment, we tested whether the CTX0E16 hNPC 224 
line (30, 31) would constitute an appropriate model. We measured expression of the NT5C2 225 
main RefSeq transcripts (NM_012229 and NM_001134373) in these cells, specifically in 226 
hNPCs and immature neuronal cultures terminally differentiated for 28 days (DD28) which 227 
we previously showed to comprise of neurons (~80%) and glial cells (~10%) (30, 31). The 228 
expression of NT5C2 RefSeq transcripts NM_012229 and NM_001134373 in hNPCs (Day 229 
0; NM_012229: 94.22 ± 5.85; NM_001134373: 85.67 ± 9.77) was 30% higher in hNPCs 230 
compared to DD28 cultures on average (NM_012229: 45.09 ± 5.59; NM_001134373: 70.45 231 
± 2.93; t-tests: NM_012229, t(6) = 12.14, P < 0.001, Bonferroni corrected P < 0.001; 232 
NM_001134373, t(6) = 2.99, P < .0245, Bonferroni corrected P = 0.049). These findings are 233 
consistent with higher expression at an earlier developmental stage with persistent 234 
expression after differentiation (Figure 2B).  235 
 236 
As sub-cellular protein distribution can inform gene function, we immunolabelled hNPCs 237 
from the CTX0E16 and human induced pluripotent stem cell lines (hiPSC) to study NT5C2 238 
localisation. We ectopically expressed a myc-tagged NT5C2 construct in hiPSC-NPCs, and 239 
labelled these cells using myc or NT5C2 antibodies, which revealed that myc-NT5C2 was 240 
abundantly expressed in punctate structures in the cell soma and along neurites (Figure 241 
2C; Supplemental Figure 4). Similarly, endogenous NT5C2 was distributed in punctate 242 
structures through the cell and neurites (Figures 2D and E), suggesting that this protein is 243 
ubiquitously distributed in hNPCs, consistent with the expected distribution of a cytosolic 244 
protein. 245 
 246 
NT5C2 regulates the phosphorylation of AMPK and ribosomal protein S6 (RPS6)  247 
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The knockdown of NT5C2 activates AMPK signalling in muscle fibres (21), and considering 248 
the relevance of AMPK to psychiatry (17-20), we tested whether this also occurred in 249 
hNPCs. The knockdown in CTX0E16 hNPCs was performed using two independent small 250 
interfering RNA (siRNA) sequences, A and B. Initially, the transfection protocol efficacy was 251 
determined by assessing the uptake of fluorescently labelled oligonucleotides (BLOCK-iT), 252 
which revealed a transfection rate of 90% ± 0.02 (n = 4 biological replicates per condition, 4 253 
technical replicates each; Figure 3A). We obtained knockdown cultures and confirmed 254 
reduced NT5C2 expression using RT-qPCR (linear regression to identify the effect of 255 
siRNAs on NT5C2 expression controlling for biological replicate and qPCR batch: F(2, 5) = 256 
13.9, P = 0.009, R2 = 0.92; Tukey post hoc tests against scramble (3.29 (dCt) ± 0.23 257 
(standard deviation)): siRNA A (3.79 ± 0.09), fold-change = 0.71, P = 0.005; siRNA B (3.29 258 
± 0.23), fold-change = 0.81, P = 0.028; Figure 3B). The ability of these siRNAs to 259 
knockdown NT5C2 protein was further assessed in independent cultures (Figures 3C and 260 
D), which revealed a significant decrease in protein abundance in knockdown conditions 261 
(One-way ANOVA, F (2, 41) = 12.23, P < 0.001; Tukey post hoc tests against scramble 262 
(100.0 ± 14.7): siRNA A (58.8 ± 34.7), P < 0.001; siRNA B (62.4 ± 21.5), P < 0.001).  263 
 264 
To test the effect of the knockdown on AMPK signalling, we measured total abundance and 265 
relative phosphorylation of AMPK-alpha, a subunit of AMPK. We observed a significant 266 
effect of the knockdown on AMPK-alpha abundance, which was associated with a mean 267 
132% increase in total protein (Kruskal-Wallis test, H(3) = 12.2, P < 0.001; Dunn’s post hoc 268 
tests against scramble (Mdn = 100.0): siRNA A (236.1), P = 0.002; siRNA B (182.8), P = 269 
0.017; Figure 3E). Additionally, we observed a significant effect of the knockdown on the 270 
relative phosphorylation of AMPK-alpha (Thr172), with the knockdown associated with a 271 
mean 55% increase in phosphorylated AMPK, suggesting activation of this cascade 272 
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(Kruskal-Wallis test, H(3) = 7.65, P < 0.013; Dunn’s post hoc tests against scramble (Mdn = 273 
100.0): siRNA A (141.2), P = 0.033; siRNA B (160.7), P = 0.033; Figure 3E).  274 
 275 
Considering that protein translation is partly regulated by AMPK (23) and is one of the most 276 
energy consuming cellular processes (47), we hypothesised that NT5C2 function could 277 
affect the rate of protein synthesis. To test this, we assessed the effects of the knockdown 278 
on the phosphorylation of ribosomal protein S6 (RPS6) (Ser235/Ser236), which is routinely 279 
used as a proxy to estimate the rate of protein translation in neurons, as it correlates with 280 
mammalian target of rapamycin complex 1 activation (mTORC1) (48). No difference was 281 
observed in total RPS6 abundance (Kruskal-Wallis test, P > 0.05; Figure 3F), but we 282 
observed that the knockdown with siRNA A was associated with a mean 23% increase in 283 
phosphorylated RPS6 (Kruskal-Wallis test, H(3) = 8.22, P = 0.002; Dunn’s post hoc test 284 
against scramble (Mdn = 100.0): siRNA A = 115.9, P = 0.012; Figure 3F). The knockdown 285 
with siRNA B elicited a mean 10% increase in RPS6 phosphorylation, but this did not survive 286 
correction (siRNA B = 110.20, P = 0.09), probably as a consequence of the less efficient 287 
knockdown achieved with this siRNA (Figure 3B).  288 
 289 
We obtained complementary evidence supporting the association between NT5C2 and 290 
AMPK and RPS6 regulation using HEK293T cells. Overexpression of pNT5C2-myc in these 291 
cells resulted in a mean 64% decrease in phosphorylated AMPK-alpha (t-test, control (no 292 
vector): 223.00 (normalised expression) ± 76.99 (standard deviation), overexpression: 81.05 293 
± 30.14, t(15) = 4.88, P < 0.001, P Bonferroni-adjusted P (4 tests) < 0.001), whilst no 294 
difference in total AMPK levels were observed (P > 0.05; Figure 3G). These results are 295 
consistent with our previous data and indicate that NT5C2 is a negative regulator of AMPK 296 
signalling. Subsequently, we observed a mean 28% decrease in total RPS6 abundance (t-297 
test, control: 159.10 ± 48.52, overexpression: 108.8 ± 48.52, t(16) = 2.88, P = 0.011, 298 
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corrected P = 0.044), and a highly significant 300% increase in RPS6 phosphorylation (t-299 
test, control: 31.03 ± 10.66, overexpression: 124.10 ± 8.20, t(16) = 20.76, P < 0.001, 300 
corrected P < 0.001; Figure 3G). The effect of exogenous NT5C2 on RPS6 here was 301 
opposite to what we observed in hNPCs, highlighting the complex and time-dependent 302 
nature of the intracellular cascades governing protein translation, which are examined in the 303 
discussion.  304 
 305 
NT5C2 is associated with transcriptional changes implicated in protein translation 306 
In order to determine the regulatory gene networks governing the effect of NT5C2 on AMPK 307 
signalling in hNPCs, we profiled the transcriptome of these cultures using microarrays 308 
(Figures 4A and B). We aimed to characterise expression differences that were shared 309 
between both siRNA treatments, to reduce off-target effects associated with individual 310 
siRNAs (49). The concordant transcriptomic changes consisted of an overlap of 69 genes 311 
(Figure 4C), which is statistically unlikely to occur by chance (genes in microarray = 21,196; 312 
affected by siRNA A: 881 genes; siRNA B: 741 genes; Fisher’s exact test, P < 0.001, 313 
Jaccard index < 0.001, odds ratio = 2.6; gene list in Supplemental Table 1). We observed 314 
that there was a high correlation between samples within the same siRNA groups, despite 315 
the modest number of overlapping, differentially expressed genes (Pearson’s r > 0.99, P < 316 
0.001 for all correlations; siRNA A, n = 3 biological replicates; siRNAs B and scramble, n = 317 
4). The list of overlapping gene expression changes was subdivided by directionality of 318 
effect, and the up- and downregulated gene network topologies were calculated using 319 
GeneMania (50) (Supplemental Figure 5). This analysis revealed multiple connections 320 
between genes due to co-expression and co-localisation, corroborating their functional 321 
association. The up- and downregulated gene lists were analysed for enrichment of gene 322 
ontology (GO) terms (Figure 4D, Supplemental Table 2), which revealed downregulated 323 
genes (q < 0.05) pertaining to the regulation of protein translation, and of the cytoskeleton 324 
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(which is highly dependent on the transcriptional machinery (51)). Furthermore, ribosomal 325 
genes including RPL15, RPL22, RPL5 and RPL6, were downregulated, consistent with 326 
activation of AMPK signalling and inhibition of protein translation. The top upregulated GO 327 
term suggested the involvement of NT5C2 in cell adhesion, but this was not significant after 328 
correction (q > 0.05).  329 
 330 
We used RT-qPCR to validate a panel of gene expression changes observed in the 331 
microarray analysis (Supplemental Figure 6), which were related to protein translation and 332 
AMPK signalling, including the heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1), 333 
the proteasome 26S subunit, ATPase 4 (PSMC4), and the autophagy-related cysteine 334 
peptidase gene (ATG4B). HNRNPA1 is involved in protein translation (52), while ATG4B 335 
regulates AMPK signalling and energy homeostasis (53), and PSMC4 physically interacts 336 
with AMPK (54) and is involved in Parkinson’s disease (55). Considering the effects of 337 
NT5C2 in AMPK and RPS6 regulation, the transcriptional changes observed here 338 
corroborate a role for NT5C2 on protein translation, providing evidence of the gene networks 339 
involved.  340 
 341 
Knockdown of CG32549 in Drosophila melanogaster is associated with impaired 342 
climbing  343 
Considering the genetic link between NT5C2 and disorders associated with psychiatric and 344 
psychomotor disturbances, and the importance of AMPK in energy consuming tasks such 345 
as motility (19, 56), we investigated a potential role of Drosophila’s NT5C2 homologue in 346 
climbing. The human NT5C2 protein shares 60.5% sequence identity and 80.2% sequence 347 
similarity with CG32549 (Supplemental Figure 7), suggesting that these proteins exert the 348 
same or similar function. To investigate the role of CG32549 in motility whilst controlling for 349 
potential confounding effects in muscles, we generated flies using the Gal4-UAS system to 350 
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obtain crosses with reduced expression of this gene ubiquitously (driven by ACT5C 351 
promoter), in neurons and neural progenitor cells (ELAV), or in gut, as a control (GUT; 352 
Figure 5A). The ubiquitous knockdown was associated with reduced CG32549 expression 353 
in the brain (UAS line (control, no RNAi cassette) = 0.042 (dCt) ± 0.027; UAS-KD 354 
(knockdown) flies = 0.007 ± 0.004; fold-change = 0.88; t-test: t(6) = 2.6, P = 0.043, n = 4; 355 
Figure 5B). No difference in survival was observed across genotypes (UAS versus UAS-356 
KD lines, t-tests, P > 0.05, n = 5 flasks on average; Figure 5C). We observed a significant 357 
impairment in climbing success associated with the knockdown using the ELAV promoter 358 
(UAS = 96.9% ± 2.2, UAS-KD = 85.2% ± 8.5; t(11) = 3.53, P = 0.005, adjusted P = 0.014, n 359 
= 7 per condition on average; Figure 5D). There was also a nominally significant reduction 360 
in climbing success upon knockdown of CG32549 using the ACT5C promoter (UAS = 90.6% 361 
± 9.7, UAS-KD = 77.7% ± 13.4, t-test: t(17) = 2.4, P = 0.029, n = 10 per condition on average, 362 
Bonferroni P (adjusted for 3 comparisons) > 0.05). This impairment was not observed in flies 363 
with the knockdown in gut (UAS = 98.5% ± 2.3, UAS-KD = 97.4% ± 2.3, t-test, P > 0.05, n = 364 
8 per condition on average). These findings suggest there is an effect of neuronal CG32549 365 
in D. melanogaster motility, and provide an insight at the function of NT5C2 at a systems 366 
level. 367 
 368 
 369 
Discussion 370 
The NT5C2 gene is implicated in risk for psychiatric and neurological conditions (1-3, 5, 6) 371 
and it has been recently classified as a high confidence schizophrenia risk gene by 372 
PsychENCODE (4), but the biological mechanisms responsible for these associations 373 
remain elusive. We previously showed that psychiatric risk alleles at the NT5C2 locus are 374 
associated with reduced expression of this gene in the adult and developing brain (3). Here, 375 
we observe that reduced NT5C2 expression is associated with differential regulation of 376 
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AMPK signalling and RPS6 in hNPCs, suggesting a regulatory role on energy homeostasis 377 
and protein translation. We also observe that neurological expression of NT5C2 peaks 378 
during neurodevelopment but persists at later developmental stages, corroborating our 379 
previous hypothesis that the NT5C2 risk mechanism is an ongoing process that starts from 380 
embryonic development (3). The cell-type specific NT5C2 expression profile observed in the 381 
adult brain further revealed an enrichment for neuronal expression, suggesting that reduced 382 
NT5C2 expression in the mature cortex could be particularly detrimental to neurons. These 383 
findings are consistent with recent studies showing that schizophrenia risk variants are 384 
enriched for genes implicated in neurodevelopment and neuronal function (40, 57).  385 
 386 
The manipulation of NT5C2 expression in hNPCs and HEK293T cells corroborate the 387 
existence of a complex regulatory network governing protein translation, with observations 388 
suggesting, at first glance, opposing effects of AMPK on the rate of protein synthesis. 389 
However, on closer inspection, we observed that our findings with HEK cells corroborate 390 
that AMPK activation inhibits protein translation by repressing mTORC1 and eEF2 (23, 24, 391 
58, 59). Our findings with the hNPC model, in turn, corroborate AMPK activation leading to 392 
increased rates of protein synthesis over time, despite an initial period in which translation 393 
is halted, likely due to a negative feedback loop (60). As a result, we observed increased 394 
abundance of AMPK-alpha in these cultures, while no differences in expression of AMPK 395 
transcripts were detected.  396 
 397 
We also observed that a knockdown of the NT5C2 homologue CG32549 in D. melanogaster 398 
was associated with abnormal climbing behaviour, more specifically when driven by a 399 
neuronal promoter, supporting a role for NT5C2 in motility. It is unrealistic to correlate fly 400 
motility with complex psychomotor disturbances experienced by patients, but our results 401 
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corroborate previous genetic associations between NT5C2 and diseases associated with 402 
motor symptoms (1-6). The effect of CG32549 could be mediated by regulation of AMPK 403 
signalling and RPS6 activation, which are implicated in Drosophila motility (61, 62). A study 404 
showed that CG32549 is downregulated in a Drosophila model of seizure (28), and work by 405 
another group demonstrated that distance moved during seizure-like activity can be reduced 406 
(rescued) upon AMPK activation using the drug metformin (29).  407 
 408 
There are limitations to our study which should be acknowledged. First, we obtained a 409 
modest knockdown of NT5C2 in hNPCs, which we hypothesise this to be due to the 410 
proliferative nature of these cells. To support the link between NT5C2, AMPK signalling and 411 
RPS6 activation, we overexpressed NT5C2 in HEK293T cells and confirmed the differential 412 
regulation of AMPK and RPS6. Second, we observed a modest overlap of differentially 413 
expressed genes between siRNA treatments, which we hypothesise to be due to the low 414 
specificity associated with the siRNAs. This could be overcome by using a more effective 415 
gene silencing method, such as CRISPR interference (63). Third, we quantified the rate of 416 
protein translation using relative abundance of phosphorylated RPS6, but we did not 417 
investigate overall protein synthesis using methods such as the surface sensing of 418 
translation (SUnSET) (64). We have, however, provided support for the role of NT5C2 on 419 
protein translation at the transcriptional level using our microarray and RT-qPCR data.  420 
 421 
By exploring the role of NT5C2 in neurobiology, we observe that the study of individual risk 422 
factors for complex disorders has the potential to advance our understanding of common 423 
biological pathways contributing to disease. Functional studies using model organisms or 424 
cell culture may not entirely capture the heterogeneity and complexity of psychiatric 425 
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disorders, but may have potential to accelerate the identification of novel drug targets and 426 
biomarkers for psychiatric disorders.  427 
 428 
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Figure legends 626 
 627 
Figure 1. Distribution of the psychiatric risk protein NT5C2 in DLPFC sections of post-628 
mortem unaffected patients. (A) Co-localisation of NT5C2 staining with MAP2 (neuronal 629 
marker), (B) PARVALB (interneuron marker), (C) GFAP (glial marker), (D) and IBA1 630 
(microglia marker). Scale bars are 50 µM. (E) Quantification of the co-localisation of NT5C2 631 
with markers from A to D revealed a cell-type specific expression of NT5C2 in the mature 632 
cortex (one-way ANOVA, Tukey pairwise comparsions: ***P < 0.001 for all comparisons). 633 
 634 
 635 
Figure 2. Neurodevelopmental expression of NT5C2, and protein distribution in 636 
human neural progenitor cells. (A) Neurological expression of NT5C2 across human 637 
development, according to the Human Brain Transcriptome Atlas (46), showing that 638 
expression peaks during foetal development. (B) The expression of NT5C2 RefSeq 639 
transcripts NM_012229 and NM_001134373 in hNPCs (Day 0) and cultures differentiated 640 
for 28 days (DD28). Expression is significantly higher at the neural progenitor state (t-tests: 641 
***P < 0.001, *P < 0.05). (C) Distribution of ectopic NT5C2 was assessed by transfecting 642 
hNPCs with pNT5C2-myc and peGFP plasmids, followed by immunolabelling using 643 
antibodies raised against myc or GFP (GFP was used as morphological marker). (D) 644 
Subcellular localisation of endogenous NT5C2 in hNPCs derived from a hiPSC line, and 645 
from (E) the CTX0E16 cell line. NT5C2 was ubiquitously distributed in hNPCs from both 646 
models. Scale bars are 20 µM. 647 
 648 
 649 
Figure 3. Knockdown of NT5C2 in hNPCs is associated with differential 650 
phosphorylation of AMPK and RPS6. (A) The efficacy of the siRNA transfection was 651 
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determined by uptake of BLOCK-iT, a fluorescently labelled oligonucleotide. (B) NT5C2 652 
expression was significantly reduced in knockdown cultures (linear regression, Tukey post 653 
hoc tests, **P < 0.01, *P < 0.05). (C, D) The ability of the siRNA treatments to significantly 654 
reduce NT5C2 expression in independent hNPC cultures at the protein level (one-way 655 
ANOVA, Tukey post hoc tests, ***P < 0.001). (E) The NT5C2 knockdown was associated 656 
with increased total AMPK-alpha, and in phosphorylated AMPK-alpha (Thr172) in hNPCs 657 
(Kruskal-Wallis test, Dunn’s post hoc tests, **P < 0.01, *P < 0.05). (F) The knockdown did 658 
not alter total RPS6 levels, but was associated with increased phosphorylated RPS6 659 
(Ser235/Ser236). siRNA A was associated with a mean 23% increase in phosphorylation 660 
(Kruskal-Wallis test, Dunn’s test, *P < 0.05), and siRNA B a modest 10% mean increase, 661 
which was not significant after correction (P = 0.09). Full blots for E and F are available in 662 
Supplemental Figure 8. (G) The overexpression of NT5C2 in HEK293T cells causes a 663 
significant decrease in phosphorylated AMPK-alpha levels and in total RPS6, and a 664 
significant increase in phosphorylated RPS6 (t-test, ***P < 0.001, *P < 0.05). Full blots are 665 
available in Supplemental Figure 9. 666 
 667 
 668 
Figure 4. Transcriptional changes associated with the knockdown corroborate a role 669 
for NT5C2 on protein translation. (A) Volcano plots indicating nominally significant 670 
transcriptomic changes elicited by siRNA A, and (B) siRNA B. (C) Venn diagrams indicating 671 
the number of genes differentially regulated by siRNA A and B, and the overlapping gene 672 
set, which is unlikely to occur by chance, according to a Fisher’s exact test (P < 0.001). (D) 673 
Gene ontology terms enriched within genes concordantly, differentially expressed in both 674 
knockdown conditions. The line indicates the significance threshold (-log10 q < 0.05)). 675 
 676 
 677 
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Figure 5. The knockdown of CG32549 (NT5C2 homologue) in D. melanogaster using the 678 
UAS-Gal4 system. CG32549-RNAi was induced ubiquitously (ACT5C promoter), in gut 679 
(GUT), or in neural progenitor cells and neurons (ELAV). (A) Experimental design of the 680 
knockdown. (B) CG32549 was less expressed in the brain of knockdown flies (t-test, *P < 681 
0.05). (C) There was no difference in survival percentage between UAS lines vs UAS-682 
knockdown lines 17-20 days post eclosure (t-tests, P > 0.05). (D) Climbing success 683 
observed in UAS lines vs UAS-knockdown lines highlights the effect of ubiquitous, neuron- 684 
or gut-specific knockdowns on motility (t-tests, *P < 0.05, **P < 0.01), but not in gut (P > 685 
0.05).  686 
 687 
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